Magtrace and Sentimag received positive recommendations from MTP Council in Sweden

In April 2023, Swedish Medical Technologies Product (MTP) Council completed the assessment of Magtrace and Sentimag technology within the Orderly introduction framework. In this framework launched in 2020, all Swedish regions collaborate to manage the national introduction of innovative medical technologies via a staged process: horizon scanning, selection of the method for evaluation, the decision on national collaboration, health economic evaluation, and recommendations by the MTP Council to regions about the introduction of the method and criteria for use.

Magtrace is a magnetic fluid that is injected near a tumor. The fluid is then tracked using a sensor, Sentimag, to investigate the possible spread of breast cancer cells to sentinel lymph nodes before surgery. In April 2022, MTP Council commissioned the TLV to perform a health economic evaluation of Magtrace and Sentimag technology, which was completed in January 2023.

MTP Council recommended that Magtrace and Sentimag be used for locating sentinel lymph nodes in patients undergoing breast cancer surgery. The clinical evidence shows equivalent effectiveness of Magtrace and Sentimag compared to standard care - sentinel nodes scintigraphy. However, there are other advantages, such as the fact that nuclear medicine equipment is not required, as in the case of scintigraphy. According to the health economic evaluation by TLV, the cost of Magtrace and Sentimag is higher than scintigraphy, but other benefits can outweigh it.

See more information here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.